StemCell Therapy

Auditory neuropathy was first described in 1996 by Arnold Starr, MD, and colleagues as a hearing impairment that, by behavioral and physiological testing, were compatible with a disorder of the auditory portion of the eighth cranial nerve.1 Since then, research has found notable hallmarks of normal outer hair cell function in the presence of severely abnormal or absent auditory brainstem evoked potentials. When measurable, speech discrimination scores are proportionally lower than expected for the degree of hearing loss, complementing a patient's hearing difficulty (e.g., I can hear sound but can't understand speech, especially in noise). Also, a host of neurological, audiological, and clinical features and findings reveals a variety of causes, genotypes and phenotypes, comorbidities, and auditory consequences. The desynchrony created by auditory neuropathy impairs neural processing, thereby resulting in a series of perceptual disadvantages and compromiseand to various degrees, disabling communication and auditory scene analysis. Whether occuring from a peripheral or a central site, the effects of temporal discord are universal: Auditory temporal processing determines our understanding of speech, our appreciation of music, being able to localize a sound source, and to listen to a person in a noisy crowd.2

Auditory system delineating the inner hair cells (sensory), pre- and postsynaptic portions (synapse), and the spiral ganglion and auditory nerve (neural). Cochlear implantation bypasses the sensory and synaptic portions providing a time-locked signal to the neural partition.6 Health loss, research, neuropathy.

Since the discovery of auditory neuropathy, researchers have described various sites of the lesion along the neural pathway. Auditory neuropathy is a condition of abnormal neural encoding of acoustic signals in the presence of normal sensory transduction and amplification properties of the outer hair cells.3 Potential disorders and sites of lesions include (1) presynaptic disorders affecting inner hair cells and ribbon synapses; (2) postsynaptic disorders affecting unmyelinated auditory nerve dendrites; (3) postsynaptic disorders affecting auditory ganglion cells and their myelinated axons and dendrites; and (4) central neural pathway disorders affecting the auditory brainstem.4 In some cases, auditory neuropathy may include brainstem connections such as those reported in individuals with multiple brainstem neuropathies.5 These structures are divided into three primary partitions responsible for encoding sound: sensory, synaptic, and neural (Fig. 1).6

Fortunately, advancements in auditory electrophysiology and psychophysical tests have made the identification of the site of lesion and functionality more available to clinical practice. These tools have greatly improved diagnosis, treatment selection, and outcome prediction. Having a basic understanding of this complex topic is useful for audiologists and ENT physicians because auditory neuropathy spectrum disorders (ANSDs) occur in children, adults, and seniors due to aging, noise exposure, trauma, and disease. Take note of these pearls of wisdom that will aid in evaluating, diagnosing, and discussing hearing loss and treatments with patients of all ages.

Research highlights relevant to audiology practices include notable information on ANSD prevalence, causations, symptoms, evaluation, testing, and treatments.

PREVALENCE. One in 7,000 neonates evaluated through newborn hearing screening has been found to have an abnormal auditory nerve function.4 ANSD is estimated to occur in one in 10 children with permanent hearing loss.7 Studies suggest that a considerable number of cases may occur in the well-baby population since newborn hearing screenings are typically based on otoacoustic emissions (OAEs)8 rather than auditory brainstem response (ABR)7 or simultaneous testing.

The incidence of patients with auditory neuropathy or cochlear synaptopathy9 in the general population is unknown. However, 10 percent of patients seen at Massachusetts Eye and Ear complain of hearing difficulty in the presence of clinically normal hearing,10 suggesting that ANSD and central auditory processing disorder (CAPD) evaluations should be considered for this population.

CAUSATION. Syndromic and nonsyndromic disorders cause auditory neuropathy through synaptic and neural pathways. Auditory neuropathy varies by etiology, onset age, site of lesion, auditory behavior, and the presence or absence of other peripheral neuropathies.11 Prematurity, low birth weight, hyperbilirubinemia, anoxia, otoferlin gene mutations, Waardenburg's syndrome, Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy), ototoxic drugs, infection, and cranial nerve hypoplasia, among others, have been reported as risk factors. Genetic disorders account for most cases, especially in children. A mild head injury can cause cranial nerve injury, including an injury to the eighth nerve, although this is less frequent.12

Auditory synaptopathy impairs sound encoding at the synapses between inner hair cells and spiral ganglion neurons.3 Should discrimination difficulty accompany normal hearing sensitivity by standard audiometry (some with ultra-high-frequency hearing loss) and a history of noise exposure or advanced aging, the patient may have cochlear synaptopathy or hidden hearing loss.13

SYMPTOM. Psychophysical testing reveals auditory neuropathy results in perceptual consequences that impair speech discrimination and auditory scene analysis. Unlike cochlear impairments, this condition has a minor effect on loudness, high-frequency pitch discrimination, or localization based on level differences. On the other hand, auditory neuropathy patients have deficiencies in time-based perceptions such as pitch discrimination at low frequencies, temporal integration and modulation detection, binaural beats, masking paradigms, hearing signals in noise, gap detection, and localization using interaural timing.14

Children with this condition may have excellent visual cognition but exhibit poor auditory skills.15 Speech may develop normally or be delayed. Speech discrimination may range from no difficulty in quiet with issues hearing in noise to profound hearing loss in quiet.7

Adults who acquire auditory neuropathy complain of difficulty understanding speech and deafness in background noise. They have difficulty with music perception, sound fading, and localization, and often dislike noise. They may be unemployable for certain jobs, cannot hear well on the telephone, and prefer online jobs and email for communication.

Patients with auditory neuropathy may have constant low-frequency bilateral tinnitus (< 1,000 Hz) with pitch matching at the greatest degree of hearing loss, typically 10 to 15 dB SL.16

In cases of comorbid peripheral neuropathy or a diagnosis of Charcot-Marie-Tooth disease (the most common inherited neurological disease), hearing loss occurs several years before the onset of other symptoms.3

Auditory neuropathy may be progressive as a result of several conditions. These include genetic mutations, mitochondrial disorders, autoimmune anomalies, degenerative changes from aging and noise trauma, toxic metabolic disorders, and nutritional deficits.3

Mutations of the OTOF gene (otoferlin) can express as a transient temperature-sensitive auditory neuropathy, which resolves once the increased body temperature is resolved.17,18 A gene responsible for autosomal dominant auditory neuropathy (AUNA1) was found in a family of European ancestry. The average age of symptom onset was 19 years old.19

EVALUATION. Audiological testing may cover a wide variety of evaluations depending on the patient's age. These may include testing of pure tones, hearing in noise, otoacoustic emissions with and without crossed suppression, acoustic reflexes, cochlear microphonics, summating potentials, ABR, and cortical auditory-evoked potential (CAEP), as well as tympanometry and electrocochleography (ECochG).

Medical evaluation includes an MRI of the inner ears, retrocochlear and brainstem structures, a complete history and genetic analysis, and a physical examination. Audiometric configurations can be downsloping, flat, or high frequency. Low-frequency or reverse curve loss is more prominent, potentially as a result of phase-locking difficulty caused by desynchrony compared to higher frequencies at approximately 2,000 Hz.1

In some cases of auditory neuropathy, patients may have abnormalities in the cochlear microphonic, low amplitude wave V without a wave I, and absent TEOAEs.20 Despite compromised ABRs, CAEPs can often be recorded in ANSD patients. Emerging research highlights the application of CAEP in estimating the behavioral thresholds in this population.21 A slower time constant and recovery allow for better synchrony and reliability.

Vestibular neuropathy may accompany findings of auditory and peripheral neuropathies. Some patients with abnormal caloric responses may be asymptomatic in the presence of peripheral neuropathy.22 The prevalence of at least one vestibular complaint with auditory neuropathy is 20 percent.23 Using the Dizziness Handicap Inventory, the severity of balance complaints is reported as moderate.24

The British Society of Audiology has published comprehensive recommendations for testing young infants who fail newborn screening or considered at risk for ANSD. Testing for this cohort starts with a 4kHz tpABR, followed by another test to identify sensorineural or mixed hearing loss or ANSD, such as a bone conduction ABR, 1 kHz or 0.5 kHz ABR, click ABR, OAE, and/or cochlear microphonics, tympanometry, or stapedial reflexes testing.7 In premature babies, ABR retesting over weeks and months should be conducted to identify those with delayed maturation.

TREATMENT. Goals for newborns with suspected ANSD are to provide appropriate treatment and begin rehabilitation within the first six months. Visual cueing is important in the early stages until the infant's hearing level and diagnosis can be established. Hearing aids, cochlear implants (CI), and rehabilitation options are guided by the locus of the lesion, the severity of synaptic degeneration, concomitant sensory loss, neural competency, and behavioral responses.

Hearing aids are not effective in many cases, although some studies suggest that a trial with amplification, which may include wireless communication, may be recommended based on the patient's degree of hearing loss, age, comorbidities, and behavioral factors. Amplification is typically fit to standard formulas. Enhanced spectral cues and low-pass filtering in the hearing aid prescription are suggested in some cases.7

Regarding CIs, assessment of spiral ganglion health using intraoperative ECochG measurements has become one of the best predictors of CI outcomes. Cochlear implantation results are better when the site of lesion is sensory or synaptic since the CI bypasses these regions to simulate the neural partition (Fig. 1).6 A new hypothesis suggests that binaural cues improve perception in noise. Screening for residual binaural sensitivity might be important when evaluating a patient with AN's candidacy for hearing aids and/or cochlear implants.25

Based on CAEP testing, children more likely show maturation effects within six months and age-appropriate responses when CIs are fitted under the age of two.26

Thoughts on something you read here? Write to us at HJ@wolterskluwer.com

Abdala C, Sininger YS, Starr A (2000). Distortion product otoacoustic emission suppression in subjects with auditory neuropathy, Ear Hear, Dec; 21(6), 542-553. DOI:10.1097/00003446-200012000-00002

CDC (2017). Hearing loss in children; 2017 Hearing Screening Summary. Retrieved online. https://www.cdc.gov/ncbddd/hearingloss/2017-data/01-data-summary.html

Jutras B, Russell LJ, Hurteau AM, Chapdelaine M (2003). Auditory neuropathy in siblings with Waardenburg's syndrome, Int J Ped Otorhinolaryngol, Oct; 67(10), 1133-1142. DOI: 10.1016/s0165-5876(03)00200-3

More:
Updates on Auditory Neuropathy Spectrum Disorder : The Hearing Journal - LWW Journals

DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Companys Board of Advisors.

Mr. Tormeys most recent position was CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. For over four decades, Mr. Tormey has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known life sciences companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson).

"Its really great to have Terry join our corporate advisory board and team of experts at Kannalife. His experience, vision and extraordinary body of knowledge in the life sciences industry come at a perfect time for us as we start to design our commercialization and distribution plan for Atopidine, said Dean Petkanas, CEO of Kannalife.

I am honored to serve as an advisor to Kannalife. They have remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN), which, when approved, will help improve the lives of hundreds of thousands of patients, Tormey said.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

Atopidine is Kannalifes novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.

KLS-13019 is Kannalifes leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors - GlobeNewswire

COVID-19 Impact on Peripheral Neuropathy Treatment Market, Global Research Reports 2020-2021

In 2019, the global COVID-19 Impact on Peripheral Neuropathy Treatment Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

COVID-19 Impact on Peripheral Neuropathy Treatment Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global COVID-19 Impact on Peripheral Neuropathy Treatment Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The COVID-19 Impact on Peripheral Neuropathy Treatment Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the COVID-19 Impact on Peripheral Neuropathy Treatment Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-133713

Top key players @ Major competitors identified in this market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals, TEVA Pharmaceutical Industries, Immune Pharmaceuticals, etc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of COVID-19 Impact on Peripheral Neuropathy Treatment Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global COVID-19 Impact on Peripheral Neuropathy Treatment Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Peripheral Neuropathy Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the key market trends impacting the growth of the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the challenges to market growth?

Who are the key vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the market opportunities and threats faced by the vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Peripheral Neuropathy Treatment Market;

3.) The North American COVID-19 Impact on Peripheral Neuropathy Treatment Market;

4.) The European COVID-19 Impact on Peripheral Neuropathy Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Peripheral Neuropathy Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @https://www.lexisbusinessinsights.com/request-sample-133713

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Go here to read the rest:
COVID-19 Impact on Peripheral Neuropathy Treatment Market to Witness a Pronounce Growth During 2020-2025, Top key players are Eli Lilly, Johnson &...

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Neuropathy Pain Treatment market. It informs readers about key trends and opportunities in the global Neuropathy Pain Treatment market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Neuropathy Pain Treatment market.

Key companies operating in the global Neuropathy Pain Treatment market include , Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals, Neuropathy Pain Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1436343/global-neuropathy-pain-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Neuropathy Pain Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Neuropathy Pain Treatment Market Segment By Type:

, Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Other

Global Neuropathy Pain Treatment Market Segment By Application:

, Retail Pharmacies, Hospitals, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Neuropathy Pain Treatment market.

Key companies operating in the global Neuropathy Pain Treatment market include , Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals, Neuropathy Pain Treatment

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1436343/global-neuropathy-pain-treatment-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Neuropathy Pain Treatment Revenue1.4 Market Analysis by Type 1.4.1 Global Neuropathy Pain Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Calcium Channel Alpha 2-delta Ligands 1.4.3 Serotonin-norepinephrine Reuptake Inhibitors 1.4.4 Others1.5 Market by Application 1.5.1 Global Neuropathy Pain Treatment Market Share by Application: 2020 VS 2026 1.5.2 Retail Pharmacies 1.5.3 Hospitals 1.5.4 Others1.6 Coronavirus Disease 2019 (Covid-19): Neuropathy Pain Treatment Industry Impact 1.6.1 How the Covid-19 is Affecting the Neuropathy Pain Treatment Industry 1.6.1.1 Neuropathy Pain Treatment Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Neuropathy Pain Treatment Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Neuropathy Pain Treatment Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Neuropathy Pain Treatment Market Perspective (2015-2026)2.2 Neuropathy Pain Treatment Growth Trends by Regions 2.2.1 Neuropathy Pain Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Neuropathy Pain Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Neuropathy Pain Treatment Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Neuropathy Pain Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Neuropathy Pain Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Neuropathy Pain Treatment Players by Market Size 3.1.1 Global Top Neuropathy Pain Treatment Players by Revenue (2015-2020) 3.1.2 Global Neuropathy Pain Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Neuropathy Pain Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Neuropathy Pain Treatment Market Concentration Ratio 3.2.1 Global Neuropathy Pain Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Neuropathy Pain Treatment Revenue in 20193.3 Neuropathy Pain Treatment Key Players Head office and Area Served3.4 Key Players Neuropathy Pain Treatment Product Solution and Service3.5 Date of Enter into Neuropathy Pain Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Neuropathy Pain Treatment Historic Market Size by Type (2015-2020)4.2 Global Neuropathy Pain Treatment Forecasted Market Size by Type (2021-2026) 5 Neuropathy Pain Treatment Breakdown Data by Application (2015-2026)5.1 Global Neuropathy Pain Treatment Market Size by Application (2015-2020)5.2 Global Neuropathy Pain Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Neuropathy Pain Treatment Market Size (2015-2020)6.2 Neuropathy Pain Treatment Key Players in North America (2019-2020)6.3 North America Neuropathy Pain Treatment Market Size by Type (2015-2020)6.4 North America Neuropathy Pain Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Neuropathy Pain Treatment Market Size (2015-2020)7.2 Neuropathy Pain Treatment Key Players in Europe (2019-2020)7.3 Europe Neuropathy Pain Treatment Market Size by Type (2015-2020)7.4 Europe Neuropathy Pain Treatment Market Size by Application (2015-2020) 8 China8.1 China Neuropathy Pain Treatment Market Size (2015-2020)8.2 Neuropathy Pain Treatment Key Players in China (2019-2020)8.3 China Neuropathy Pain Treatment Market Size by Type (2015-2020)8.4 China Neuropathy Pain Treatment Market Size by Application (2015-2020) 9 Japan9.1 Japan Neuropathy Pain Treatment Market Size (2015-2020)9.2 Neuropathy Pain Treatment Key Players in Japan (2019-2020)9.3 Japan Neuropathy Pain Treatment Market Size by Type (2015-2020)9.4 Japan Neuropathy Pain Treatment Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Neuropathy Pain Treatment Market Size (2015-2020)10.2 Neuropathy Pain Treatment Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Neuropathy Pain Treatment Market Size by Type (2015-2020)10.4 Southeast Asia Neuropathy Pain Treatment Market Size by Application (2015-2020) 11 India11.1 India Neuropathy Pain Treatment Market Size (2015-2020)11.2 Neuropathy Pain Treatment Key Players in India (2019-2020)11.3 India Neuropathy Pain Treatment Market Size by Type (2015-2020)11.4 India Neuropathy Pain Treatment Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Neuropathy Pain Treatment Market Size (2015-2020)12.2 Neuropathy Pain Treatment Key Players in Central & South America (2019-2020)12.3 Central & South America Neuropathy Pain Treatment Market Size by Type (2015-2020)12.4 Central & South America Neuropathy Pain Treatment Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Pfizer 13.1.1 Pfizer Company Details 13.1.2 Pfizer Business Overview and Its Total Revenue 13.1.3 Pfizer Neuropathy Pain Treatment Introduction 13.1.4 Pfizer Revenue in Neuropathy Pain Treatment Business (2015-2020)) 13.1.5 Pfizer Recent Development13.2 Depomed 13.2.1 Depomed Company Details 13.2.2 Depomed Business Overview and Its Total Revenue 13.2.3 Depomed Neuropathy Pain Treatment Introduction 13.2.4 Depomed Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.2.5 Depomed Recent Development13.3 Eli Lilly 13.3.1 Eli Lilly Company Details 13.3.2 Eli Lilly Business Overview and Its Total Revenue 13.3.3 Eli Lilly Neuropathy Pain Treatment Introduction 13.3.4 Eli Lilly Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.3.5 Eli Lilly Recent Development13.4 Endo 13.4.1 Endo Company Details 13.4.2 Endo Business Overview and Its Total Revenue 13.4.3 Endo Neuropathy Pain Treatment Introduction 13.4.4 Endo Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.4.5 Endo Recent Development13.5 Grnenthal Group 13.5.1 Grnenthal Group Company Details 13.5.2 Grnenthal Group Business Overview and Its Total Revenue 13.5.3 Grnenthal Group Neuropathy Pain Treatment Introduction 13.5.4 Grnenthal Group Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.5.5 Grnenthal Group Recent Development13.6 Arbor Pharmaceuticals 13.6.1 Arbor Pharmaceuticals Company Details 13.6.2 Arbor Pharmaceuticals Business Overview and Its Total Revenue 13.6.3 Arbor Pharmaceuticals Neuropathy Pain Treatment Introduction 13.6.4 Arbor Pharmaceuticals Revenue in Neuropathy Pain Treatment Business (2015-2020) 13.6.5 Arbor Pharmaceuticals Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Neuropathy Pain Treatment Market 2020| Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments And...

Others

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Neuropathy Pain Treatment market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275286&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Neuropathy Pain Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Market Research Intellect

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Neuropathy Pain Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Neuropathy Pain Treatment Market, By Deployment Model

5.1 Overview

6 Neuropathy Pain Treatment Market, By Solution

6.1 Overview

7 Neuropathy Pain Treatment Market, By Vertical

7.1 Overview

8 Neuropathy Pain Treatment Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Neuropathy Pain Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=275286&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Neuropathy Pain Treatment Market Size, Neuropathy Pain Treatment Market Trends, Neuropathy Pain Treatment Market Growth, Neuropathy Pain Treatment Market Forecast, Neuropathy Pain Treatment Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Follow this link:
Neuropathy Pain Treatment Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

This open-label, single-arm, multicenter, Phase 1b/2 study enrolled patients with mTNBC who had previously received zero to two systemic therapies for metastatic disease and were stratified by prior number of therapy (Stratum 1 = 0 prior therapies; Stratum 2 = 1-2 prior therapies). As there were no dose-limiting toxicities observed in Phase 1, patients received the recommended Phase 2 dose of eribulin (1.4 mg/m2 intravenously on Day 1 and Day 8) and pembrolizumab (200 mg intravenously on Day 1) of a 21-day cycle. At the time of data cutoff (July 31, 2019), 167 patients were enrolled (of which 149 patients had confirmed PD-L1 status). The primary objectives were safety and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent imaging review. Secondary objectives included progression free survival (PFS), overall survival (OS), duration of response (DOR) and clinical benefit rate (CBR) overall and by PD-L1 status. Previous findings from ENHANCE 1 were presented during a Spotlight Session at the San Antonio Breast Cancer Symposium (SABCS) in 2017.

Updated findings presented during ASCO20 showed:

The most common treatment-emergent adverse events were fatigue (66%), nausea (57%), peripheral sensory neuropathy (41%), alopecia (40%), and constipation (37%). No deaths were considered treatment related. The most common possibly immune-related TEAEs for pembrolizumab (occurring in >3% of patients) were hypothyroidism (18%), pneumonitis (11%), hyperthyroidism (8%) and infusion-related reaction (3%).

"Treatment options for metastatic triple-negative breast cancer remain limited, despite advances in the field," said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai. "As a human health care company, we are committed to addressing cancers that remain difficult to treat, and this is evident in our ongoing investigation in triple-negative disease. As long as unmet needs exist, Eisai will persist in our efforts to innovate for patients."

This release discusses an investigational use for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Previously, data from ENHANCE 1 was reported at the San Antonio Breast Cancer Symposium in 2016 and 2017.

The study is being conducted under an existing clinical trial collaboration agreement between Eisai and Merck.

About HALAVEN(eribulin mesylate) InjectionHALAVEN (eribulin mesylate) injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Discovered and developed by Eisai, eribulin is a synthetic analog of halichondrin B, a natural product that was isolated from the marine spongeHalichondria okadai. First in the halichondrin class, eribulin is a microtubule dynamics inhibitor. Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death. Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumor biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype. Eribulin has also been shown to decrease the migration and invasiveness of human breast cancer cells.

Important Safety Information

Warnings and Precautions

Neutropenia: Severe neutropenia (ANC <500/mm3) lasting >1 week occurred in 12% of patients with mBC. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Patients with mBC with elevated liver enzymes >3 ULN and bilirubin >1.5 ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.

Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.

Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Adverse ReactionsIn patients with mBC receiving HALAVEN, the most common adverse reactions (25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).

Use in Specific PopulationsLactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.

Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.

For more information about HALAVEN, clickherefor the full Prescribing Information.

HALAVEN is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

About Eisai Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society's toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit http://www.eisai.com (for global), us.eisai.com(for U.S.) or http://www.eisai.eu (for Europe, Middle East, Africa), and connect with us on Twitter (U.S.and global) and LinkedIn(for U.S.).

SOURCE Eisai Inc.

http://www.eisai.com

Go here to see the original:
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN (eribulin mesylate) plus KEYTRUDA (pembrolizumab) in Patients...

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Originally posted here:
Medical Foods Market Predicted to Accelerate the Growth by 2017-2025 - Medic Insider

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuropathy pain treatment market and it is poised to grow by USD 1702.89 mn during 2020-2024, progressing at a CAGR of almost 5% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The presence of a large patient pool has been instrumental in driving the growth of the market.

Neuropathy Pain Treatment Market 2020-2024 : Segmentation

Neuropathy Pain Treatment Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Neuropathy Pain Treatment Market 2020-2024 : Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our neuropathy pain treatment market report covers the following areas:

This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

Neuropathy Pain Treatment Market 2020-2024 : Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the neuropathy pain treatment market, including some of the vendors such as Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi Backed with competitive intelligence and benchmarking, our research reports on the neuropathy pain treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Neuropathy Pain Treatment Market 2020-2024 : Key Highlights

Table Of Contents :

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by Drug Class

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read this article:
Research Report with COVID-19 Forecasts - Neuropathy Pain Treatment Market 2020-2024 | Presence Of Large Patient Pool To Boost Growth | Technavio -...

The Global Diabetic Neuropathy Market 2020 Research Report is a professional and in-depth study on the current state of Diabetic Neuropathy Market.

This is the latest report, covering the current COVID-19 impact on theDiabetic Neuropathy market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact are covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides the latest insights about the Diabetic Neuropathy market drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

Click here to get the short-term and long-term impact of COVID-19 on this Market:https://marketresearch.biz/report/diabetic-neuropathy-market/covid-19-impact

The Diabetic Neuropathy Market Report Covers the Following Companies:

Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc, Cephalon Inc, Meda Pharma GmbH, GlaxoSmithKline plc, NeuroMetrix Inc, Johnson & Johnson Inc, Boehringer Ingelheim GmbH, Astellas Pharma Inc

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants to understand the competitive scenario to plan future strategies.

For Better Understanding, Download FREE Sample PDF Copy of Diabetic Neuropathy Market Research Report :https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

The Report Provides:

An overview of the Diabetic Neuropathy market

Current COVID-19 impact on the Diabetic Neuropathy market

Comprehensive analysis of the market

Analyses of recent developments in the market

Events in the market scenario in the past few years

Emerging market segments and regional markets

Segmentations up to the second and/or third level

Historical, current, and estimated market size in terms of value and volume

Competitive analysis, with company overview, products, revenue, and strategies.

An impartial assessment of the market

Strategic recommendations to help companies increase their market presence

Download FREE Sample PDF Copy Now!

The Diabetic Neuropathy Market Report Addresses the Following Queries:

What is the estimated size of the market by 2029?

Which segment accounted or a large share of the market in the past?

Which segment is expected to account the largest market share by 2029?

Which governing bodies have approved the use of Diabetic Neuropathy?

Which region accounts for a dominant share of the market?

Which region is anticipated to create lucrative opportunities in the market?

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

Europe (Germany, the UK, France, and Rest of Europe)

North America (the US, Mexico, and Canada)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (GCC Countries and Rest of the Middle East & Africa)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

Contact Us

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Read the original here:
Diabetic Neuropathy Market All-Inclusive Research Report 2020 : Includes Impact of COVID-19 On Market - Cole of Duty

Newswise BOSTON - Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute received more than $1.3 million dollars in funding for two separate research projects.

The American Association for Cancer Research (AACR) announced that in partnership with the Lung Cancer Initiative at Johnson & Johnson (LCI) it will award $1 million dollars to a multi-institutional team focused on developing digital tools to engage high-risk smokers in an innovative smoking cessation program designed to encourage behaviors that promote lung health.

This team project is co-led by Dana-Farber nurse-scientist Mary E. Cooley, PhD, RN, FAAN, whose research arose out of her experience as an advanced practice nurse working as part of a multidisciplinary team focused on treating and supporting lung cancer patients and their families. Smoking cessation, even after the diagnosis of lung cancer, is essential to improving clinical outcomes, said Cooley. Our hope is this program encourages behaviors that promote lung health and early lung cancer detection. The other co-leaders are Peter Castaldi, MD, MSC, assistant professor of medicine at Harvard Medical School and Sun S. Kim, PhD, associate professor of nursing at the University of Massachusetts.

A separate research project recently received funding from the National Institutes of Health (NIH) to study chemotherapy-induced peripheral neuropathy. The study, led by Dana-Farber nurse-scientist Robert Knoerl, PhD, RN, looks at metabolomic and genetic markers of neuropathy in adolescents and young adults with cancer.

Essentially theres only one first-line treatment for neuropathy, said Knoerl. One reason for the lack of effective treatments is that we dont understand the underlying causes of neuropathy. We hope with this study to identify potential biomarkers that can be targeted in the future.

The mission of the Cantor Center is to reduce the burden of cancer through scholarly inquiry and rigorous research. The focus of the Centers research is the patient/family experience of living with cancer, as well as survivorship issues post-treatment.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is one of the worlds leading centers of cancer research and treatment. It is ranked in the top 5 of U.S. News and World Reports Best Hospitals for both adult and pediatric cancer care. Dana-Farbers mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

Go here to read the rest:
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services awarded two major research grants - Newswise

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.

After every treatment at Women & Infants Hospital in Providence, Rhode Island, the 15-year survivor of ovarian cancer adds sparkling creations to an earring tree placed there by volunteers. Patients are free to choose from and keep the jewelry that hangs there.

Dziobek also gives away jewelry when shes treated at Dana-Farber Cancer Institute in Boston. She has made rings for patients whose swollen fingers are too large for standard sizes and instructed others in bracelet-making techniques.

It makes people feel good and doing something productive while Im here gives me purpose, Dziobek, a retired nurse, says. A couple of months ago, a woman told me that my blue earrings were the only ones she could find that matched her dress for her daughters wedding. She was in the middle of her treatment and had no hair, but she had a beautiful scarf with the earrings to match her dress. It really helped, and she couldnt thank me enough. I had tears in my eyes; it was like a connection was made. You dont realize the impact you have when you do something like this.

Dziobek picked up her hobby in 2010 and was taking classes at a bead store when she experienced a recurrence of her cancer, first diagnosed in 2004. After radiation, she joined a clinical trial of intraperitoneal chemotherapy plus the targeted drug Velcade (bortezomib), but complications arose after one treatment, and she needed surgery. That was followed by six months of intravenous chemotherapy.

While recovering, Dziobek periodically reflected on a cuff bracelet shed begun before treatment. Although she was not sure if she would be able to follow the directions or do the intricate beading work due to her brain fog and neuropathy, she returned to her project. It took her three months to finish.

It helped me to focus, and I started to come out of the fog of chemo brain and my hands felt better, she recalls.

I felt like I was creating new pathways in my brain by focusing and figuring out color palette, placement of beads and measurements.

Dziobek was still part of the beading group, and her fellow members decided to help other patients enjoy a similar experience. They developed the Plum Blossom Project, bringing beaders to cancer centers to instruct patients in making bracelets. After completing a piece, each patient was gifted a beaded necklace made by volunteers. Dziobeks husband, Joe, helped raise funds for the project by selling CDs of two songs he wrote and performed, one about Plum Blossom and the other about the caregivers journey (youtube. com/watch?v=cd3DotLtwrE).

The group recently stopped working with patients who have cancer, but a few years ago Dziobek invited members to give a class for the gynecologic cancers support group at Women & Infants, where she goes twice a week for magnesium infusions to treat a long-term side effect of chemotherapy.

It made a difference for participants, especially one woman and her daughter.

The mom, who had been in treatment all day, wanted to take the class, but the daughter was burnt out and wanted to get home, Dziobek recalls. In the 15 to 20 minutes that they were selecting beads and putting their bracelets together, we could see the daughters shoulders and facial muscles relax, and the conversation changed. By the time they left, rather than a stressed-out caregiver taking care of a relative, it was now a mother-daughter relationship. They were excited about the bracelets theyd made, and their whole demeanor changed.Their story is a reminder, Dziobek says, of the importance of finding something enjoyable to do during cancer treatment, an idea she keeps front of mind as she prepares to enter a clinical trial at Dana-Farber.

Treatment really wears you down and the toll is cumulative, but if theres something you can do to help yourself at least feel a little better, do it, suggests Dziobek, who also finds meaning by volunteering with the Partnership to Reduce Cancer in Rhode Island, a community advisory group that works with the state health departments comprehensive cancer control program.

The partnership holds an annual June cancer summit, for which Dziobek is planning a survivor-led presentation to show participants how to make meditation bracelets and emphasize the health benefits of beading.

I firmly believe that we have to have some purpose each day and something to look forward to, no matter how we feel, she says. It continues to give you hope and keeps you moving forward.

See the original post:
Finding Meaning While Waiting in the Infusion Chair - Curetoday.com

- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer

- Data continue to support a NaPi2b biomarker-based patient selection strategy

- Generally well-tolerated with no new safety signals

- Data to be presented on a conference call today at 8 a.m. ET and at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020

CAMBRIDGE, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma.The Company will host a conference call and webcast today,Wednesday, May 27, 2020, at8:00 a.m. ETduring which investigatorDebra L. Richardson, MD, Associate Professor of Gynecologic Oncology at theStephenson Cancer Centerat theUniversity of Oklahoma Health Sciences Centerand theSarah Cannon Research Instituteand members of the Mersana executive team will present and discuss these data. These data will also be presented in a poster session at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020 starting at 8:00 a.m. ET.

These data demonstrate not only that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, can deliver confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer, but also that these responses can deepen over time in a patient population with poor prognosis and limited treatment options, said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. XMT-1536 continues to demonstrate that it is generally well tolerated, without the dose-limiting toxicities of other ADC platforms such as severe neutropenia, neuropathy and ocular toxicity. These are encouraging signals as we look forward to reporting more mature data in the second half of the year and continuing to advance XMT-1536 for both platinum-resistant ovarian cancer and NSCLC adenocarcinoma patients.

The expansion portion of the Phase 1 study is enrolling patients with platinum-resistant ovarian cancer, fallopian tube or primary peritoneal cancer who have received up to three lines of prior therapy and in some cases four lines of prior therapy regardless of platinum status as well as patients with NSCLC adenocarcinoma who had received prior treatment with platinum-based therapy and immunotherapy or targeted agents. With a data cutoff of May 1, 2020 these data include 34 patients total, 27 with ovarian cancer and seven with NSCLC adenocarcinoma. Patients with ovarian cancer had a median of three prior lines of treatment (range 1-5), and patients with NSCLC adenocarcinoma had a median of two lines of therapy (range 1-3).Fifteen of the patients were dosed at 36 mg/m2, and 19 patients were dosed at 43 mg/m2 every four weeks. Key findings include:

*7 patients not evaluable: 1 withdrew consent (Lower NaPi2b Expression); 1 with unrelated SAE leading to discontinuation and death (Lower NaPi2b Expression); 5 have not yet received a scan**uPR=1 patient with unconfirmed PR; confirmatory scan pending at the time of data cutHigher NaPi2b Expression: defined in dose escalation as at / above lowest H-score at which response observed (110)Lower NaPi2b Expression: defined in dose escalation as below the lowest H-score at which response observed (<110)

Conference Call DetailsMersana Therapeutics will host a conference call and webcast today at 8:00 a.m. ET during which investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute and members of the Mersana executive team will present and discuss these data. To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7785868. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at http://www.mersana.com.

About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersanas lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersanas second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersanas customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Companys early stage programs include a B7-H4 targeting ADC, as well as a STING-agonist ADC developed using the Companys Immunosynthen platform. In addition, multiple partners are using Mersanas Dolaflexin platform to advance their ADC pipelines.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on managements beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Companys business strategy and the design, progression and timing of its clinical trials and expectations regarding future clinical results based on data achieved to date. Forward-looking statements generally can be identified by terms such as aims, anticipates, believes, contemplates, continues, could, estimates, expects, goal, intends, may, on track, plans, possible, potential, predicts, projects, seeks, should, target, will, would or similar expressions and the negatives of those terms. Forward-looking statements represent managements beliefs and assumptions only as of the date of this press release. The Companys operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Companys results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later clinical trials, and that the development and testing of the Companys product candidates will take longer and/or cost more than planned, as well as those listed in the Companys Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 28, 2020, the Companys Quarterly Report on Form 10-Q filed with the SEC on May 8, 2020 and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic might adversely affect the Companys preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Companys operations and the value of and market for the Companys common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contact:

Investor & Media ContactSarah Carmody617-844-8577scarmody@mersana.com

Here is the original post:
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study - GlobeNewswire

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Reaching the revenues of over US$ 6 Bn at the end of 2019, the globalneuropathic pain management marketis projected for a healthy CAGR during the forecast period (2019 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4149

Key Takeaways Neuropathic Pain Management Market Study

Increasing prevalence of diabetic neuropathy and availability of approved neuropathy pain medications have significantly added to the opportunities for market growth, thereby fostering the rate of adoption of neuropathic pain management drugs.

Increasing R&D Spending by Pharmaceuticals Companies Shaping Future

One of the key factors observed to impact the neuropathic pain management market growth is the development of new drugs for treatment of neuropathic and chronic pains. Companies are focusing on clinical trials to develop drugs for efficient treatment of neuropathic pain. For instance, Eli Lilly and Company developed Duloxetine (LY248686) for Diabetic Peripheral Neuropathic Pain (DPNP) that is under phase 4 clinical trial.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4149

At the same time, companies are focused on expanding therapeutic applications of drugs such as opioids and steroids for neuropathic pain management without causing any serious side effects to patients. Currently, more than 100 clinical trials are been carried out for pain management. Among those clinical trials, nearly half of the clinical trials are for various indications of neuropathic pain such as diabetic neuropathy and post-herpetic neuralgia.

What Does the Report Cover?

The neuropathic pain management market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the neuropathic pain management market during 2014 2018 and presents demand projections during 2019 2029 on the basis of drug class (tricyclic anti-depressants, anticonvulsants, SNRIs, capsaicin cream, local anesthesia, opioids, steroids, and others), indication (diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others), distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies) across prominent regions (North America, Latin America, Europe, Asia Pacific and MEA).

What the report encloses for the readers:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Liquid Chromatographymass Spectroscopy MarketLiquid Chromatography-Mass Spectroscopy Segmented By Triple Quadrupole, Time of Flight, Quadrupole Technology in Clinical Testing, Environmental Testing, Forensic Testing.For More Information

Biopharmaceutical MarketBiopharmaceuticals Market Segmented By Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor, Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins Type for Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases.For More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

View post:
Neuropathic Pain Market to Witness CAGR 5.6% Growth in Revenue During the Period 2024 - WaterCloud News

THE WOODLANDS, TX - A number of Houstons aging residents are turning to non-invasive regenerative therapies to get relief from chronic pain associated with degenerative conditions like osteoarthritis, neuropathy, back and joint pain.

Doctors Jeffery Pruski, D.C., and Edward Nash, M.D., are pain management and regenerative medicine specialists at 3R Regenerative Repair & Relief (3R), located just outside of Houston in The Woodlands, Texas. Over the past three years, the doctors have seen a steady rise in patients over the age of 55 looking for alternatives to knee replacements, back surgeries, and opioid pain medications to relieve chronic pain.

As we age, the body loses its natural ability to heal itself, said Dr. Pruski. Unlike traditional pain management, which typically treats the symptoms of the pain with surgery or medications, regenerative therapies treat the root cause of the pain. It creates a healing environment inside the joint, or area of degeneration, that uses the bodys own healing capacity to regenerate healthy cells and restore normal function to damaged areas.

Older adults are more likely to experience chronic pain conditions like osteoarthritis, cancer, neuropathies and osteoporotic-related fractures.

Dr. Pruski believes more seniors are choosing regenerative therapies over traditional treatments out of concerns with taking opioid medications and because, compared to surgery, there is no trauma to the body, no anesthesia, no cutting of the skin or foreign implants; all of which pose additional health risks to one of our most vulnerable populations.

Roughly 60% of the patients treated at 3R are 55 or older. Doctors Pruski and Nash use a combination of non-invasive modalities approved by the FDA, including physical therapy, chiropractic care, regenerative medicine and biological therapy to help aging patients relieve pain and inflammation, speed recovery of injured or damaged areas, and improve their quality of life.

Dr. Pruski said while treatments vary for each individual patient, the doctors at 3R are seeing very successful outcomes treating aging patients suffering from chronic pain with the use of advanced technologies and interventions such as Regenerative Injection Therapies, Pulsed Electromagnetic Field (PEMF) therapies and Hako-Med therapy, which stimulates the nerves to provide muscle re-education and pain relief for a variety of degenerative joint conditions and nerve problems, along with muscle work, massage therapy and home exercise.

Our entire focus is preventative and regenerative care so that patients of all ages and all activity levels can maintain a healthy, pain-free life, said Dr. Pruski. We see everyone from professional and retired pro athletes, to everyday people who just want to be able to pick up their grandkids or make themselves a cup of coffee without pain. Todays technology allows us to accomplish healing and pain management goals for all of our patients in the most pain-free, non-invasive way possible. Most treatments last less than 30 minutes, require nothing more than a Band-Aid, with no recovery or down time, and you can drive yourself home.

Most insurance companies cover the majority of treatments at 3R Regenerative Repair & Relief, however coverage for biologic injection procedures may vary from policy to policy.

For more information on services and telemedicine consultations at 3R please visit https://www.3RRegenerativeMedicine.com.

See the original post:
Regenerative Therapies Helping Houston Seniors Find Non-Surgical Relief from Chronic Pain, Arthritis at Woodlands Clinic - Woodlands Online

SEATTLE, May 25, 2020 (GLOBE NEWSWIRE) -- Various lesions or diseases of the somatosensory system may lead to neuropathic pain. Nerve blockage and pharmacological remedies are used in the treatment and management of neuropathic pain.

The global neuropathic pain market is estimated to account for US$ 9,862.3 Mn in terms of value by the end of 2027.

Market Drivers:

High prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Market Opportunities:

R&D in neuropathic pain is expected to offer lucrative growth opportunities for players in the market. For instance, in May 2020, researchers from University Medical Center Hamburg-Eppendorf and other prominent universities in Germany reported that loss of C-fiber may lead to neuropathic pain in Schwannomatosis, a form of neurofibromatosis caused due to the occurrence of multiple schwannomas, tumors that develops from the Schwann cells.

Moreover, adoption of nanoparticles in therapies is also expected to aid in growth of the global neuropathic pain market. For instance, in May 2020, researchers from Chungnam National University Hospital, South Korea, reported that poly(D,L-lactic-co-glycolic acid)-encapsulated CX3CR1 small interfering RNAs nanoparticles may aid in the treatment of neuropathic pain.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3656

Key Takeaways:

The global neuropathic pain market was valued at US$ 6,313.4 Mn in 2019 and is forecast to reach US$ 9,862.3 Mn by 2027 at a CAGR of 5.6% between 2020 and 2027. Increasing prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period.

Anticonvulsants segment held dominant position in the global neuropathic pain market in 2019, accounting for 40.8% share in terms of value. Development of new drugs for the treatment of neuropathic pain is expected to drive the segment growth.

Diabetic neuropathy segment held dominant position in the global neuropathic pain market in 2019, accounting for 46.4% share in terms of value, followed by Chemotherapy-induced peripheral neuropathy and others, respectively. Increasing prevalence of diabetic neuropathy in developing economies is expected to assist the growth of the segment during the forecast period.

Market Trends:

Various studies are focused on developing alternatives to drugs in the treatment of neuropathic pain. For instance, in March 2020, researchers at the Autonomous University of the State of Hidalgo, Mexico, reported that pomegranate and secondary metabolites can be effective in the treatment of inflammatory, nociceptive, and neuropathic pain.

The market is witnessing adoption of combination therapies as an effective approach in the treatment of neuropathic pain. For instance, in March 2020, researchers from Universitat Autnoma de Barcelona, Spain, reported that NeuroHeal a combination of two repurposed drugs: Acamprosate and Ribavirin reduces the appearance of neuropathic pain in peripheral nerve injury.

Competitive Landscape:

Major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., CODA Biotherapeutics, Inc., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, Neuroheal Biomedicals, S.L., and Depomed, Inc.

Key Developments:

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in May 2020, CODA Biotherapeutics, Inc. collaborated with the Facial Pain Research Foundation for R&D of new therapies for trigeminal neuralgia and related neuropathic pain using CODAs chemogenetic gene therapy platform.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3656

Taxonomy (Scope, segments)

See more here:
Neuropathic Pain Market to reach US$ 9,862.3 Million globally by 2027 Coherent Market Insights - GlobeNewswire

BASEL, Switzerland--(BUSINESS WIRE)--Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the novel drug candidate (NRD135S.E1) for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) to evaluate NRD135S.E1 in a Phase 2 study.

Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019. The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients experiencing neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once daily for 3 months.

Submitting this IND is an important next step in the clinical development of NRD135S.E1 for the treatment of PDPN and we are moving rapidly to potentially address a global unmet medical need, said Sara Mangialaio, M.D., Ph.D., CMO and Head of R&D at Novaremed. We look forward to launching this Phase 2 study as soon as possible. This study will provide further important information about the safety and efficacy of NRD135S.E1, which was very well tolerated and induced a clinically relevant reduction in pain in the previous Phase 2 Proof of Concept study of 3-week duration.

The company is currently in discussions with potential investors to raise the necessary funding to support the conduct of the proposed Phase 2 study, as well as prepare for further late-stage development activities of NRD135S.E1.

Safe and effective therapies are critical to provide patients and physicians with treatment alternatives for PDPN, said Subhasis Roy, M.Com, MBA, CEO/COO of Novaremed. The next steps announced today for NRD135S.E1 highlight the result of Novaremeds many years of pursuit to move a novel non-opioid drug against PDPN as rapidly as possible.

Novaremed also announced today the appointment of three new members to the companys board of directors, effective May 14, 2020. Joining the board are Thomas Meier, Ph.D., Benyamin Sidon and Eliahu Kaplan, M.D. These appointments bring Novaremeds total board membership to six.

Dr. Thomas Meier is a dynamic life sciences entrepreneur who established Santhera Pharmaceuticals (SIX Exchange: SANN) as a successful Biotech/Specialty Pharma company in Switzerland. In the past 20 years he held executive positions (CSO and CEO) and successfully supported or executed mergers, acquisitions, product licensing and turn-around situations. Since 2017 he is member of Santheras Board of Directors. He holds a Ph.D. in Biology from the University of Basel and carried out post-doctoral training at the University of Colorado Health Sciences Center (USA) and Biozentrum, University of Basel, where he became group leader and lecturer in neurosciences before joining the industry. He is an internationally recognized scientist with track record in clinical research of orphan diseases (neuromuscular, neuro-ophthalmology). In 2007, he received the BioValley Basel Award for his outstanding contributions to the life sciences in the area.

Mr. Benyanin Sidon is an Investment Advisor at Gefen Biomed Investments, an Israeli public company, investing in Israeli startups with disruptive technologies. He has been active in fund raising and portfolio management activities in Israel over the last three decades. He sits on the board of directors of several portfolio companies of Gefen in Israel and abroad. He has a B.A. in Economics from Tel Aviv University, Israel.

Dr. Eliahu Kaplan is the founder, former board member and CEO of Novaremed Ltd as well as former CEO and Chief Innovator of Novaremed AG. He has more than 30 years of experience in the pharmaceutical industry particularly in oncology drug development. He worked at Farmitalia Carlo Erba in Milan, Italy as Director of Oncology Corporate Medical Department, as Medical Director in Freiburg, Germany as well as in Israel. In addition, between 1994 and 1998, he founded Seneb-Pharma, a consulting firm to consult in the field of R&D of drugs and medical products. Between 2005 and 2006 he was Medical Director (part-time) at Oridion BreathID in Israel.

We are excited to welcome Thomas, Benny and Eli to our board of directors. They bring decades of leadership in drug development and in business, that are vital to our future operations and strategy, said Isaac Kobrin, M.D., Chairman of the Board of Novaremed.

Notes to the Editor:

About Novaremed

Novaremed Ltd, a wholly owned subsidiary of Novaremed AG was founded in 2008 in Israel and Novaremed AG was founded in 2017 in Switzerland. Novaremed Ltd is developing NRD135S.E1, an orally active non-opioid small molecule with a novel mechanism of action against PDPN. In a Phase 2 Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2 study in PDPN. For more information, visit http://www.novaremed.com.

See the original post here:
Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also...

DUBLIN--(BUSINESS WIRE)--The "Global Neuropathy Pain Treatment Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

The neuropathy pain treatment market is poised to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The market is driven by the presence of large patient pool and focus toward the development of novel therapeutics for postherpetic neuralgia.This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.

The neuropathy pain treatment market analysis includes type segment and geographic landscape.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The neuropathy pain treatment market covers the following areas:

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuropathy pain treatment market vendors that include Abbott Laboratories, Assertio Therapeutics Inc. , AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi. Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.

This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Indication

Market Segmentation by drug class

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/4n7ghp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

More here:
World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer -...

A Lesser-Known Chemotherapy Side Effect

The well-known side effects of chemotherapy can usually be dealt with fairly effectively for many women, though we empathize with anyone having to go through chemo. Two of the most common chemo side effects, nausea and hair loss, can both be managed with available treatments. The same is true of another, lesser-known side effect of chemotherapy, called neuropathy.

Neuropathy is the medical term for numbness or tingling in the fingers or toes, caused by powerful chemotherapy drugs damaging the peripheral nerves. Women receiving ovarian cancer chemotherapy with the taxane (Taxol) or platinum group of drugs are particularly susceptible to this side effect of treatment.

Fortunately oncologists are usually well-versed in this side effect, and take steps to try and minimize the problem during treatment. We usually assess for the degree of neuropathy prior to every dose of chemotherapy, says Dr. Manojkumar Bupathi, a medical oncologist at Rocky Mountain Cancer Center in Littleton, Colorado. In the event that neuropathy is getting worse, we can adjust the doses or delay treatments. We can also switch a patients drugs if it becomes an ongoing issue.

Symptoms

In addition to the numbness and tingling sensations that are characteristic of neuropathy, some patients may also experience:

Treatment

Patients can try several different approaches to dealing with neuropathy. We usually ask patients to use things like ice packs or protective gloves to try and mitigate the neuropathy, says Dr. Bupathi.

When simple treatments like this dont work, patients may want to consult a neurologist who can help treat the condition with a variety of different medications, including:

Prognosis

Most neuropathy goes away and improves over time, but sometimes it can take upwards of a year before it gets better, says Dr. Bupathi. While neuropathy may be permanent, Dr. Bupathi says that it usually persists as numbness or tingling, and isnt usually debilitating, where someone isnt able to walk or do basic things like buttoning a shirt or lifting a pen off a countertop.

If youre undergoing chemotherapy and start to experience symptomsnumbness, tingling, pain or weakness in the hands and feetmake sure to let your oncologist know so that you can take steps to relieve the symptoms and prevent permanent nerve damage.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Manojkumar Bupathi is a medical oncologist with Rocky Mountain Cancer Centers. Read More

Neuropathy is the medical term for numbness or tingling in the fingers or toes, caused by powerful chemotherapy drugs damaging the peripheral nerves. Women receiving ovarian cancer chemotherapy with the taxane (Taxol) or platinum group of drugs are particularly susceptible to this side effect of treatment.

Symptoms

In addition to the numbness and tingling sensations that are characteristic of neuropathy, some patients may also experience:

Treatment

Patients can try several different approaches to dealing with neuropathy. We usually ask patients to use things like ice packs or protective gloves to try and mitigate the neuropathy, says Dr. Bupathi.

When simple treatments like this dont work, patients may want to consult a neurologist who can help treat the condition with a variety of different medications, including:

Prognosis

Most neuropathy goes away and improves over time, but sometimes it can take upwards of a year before it gets better, says Dr. Bupathi. While neuropathy may be permanent, Dr. Bupathi says that it usually persists as numbness or tingling, and isnt usually debilitating, where someone isnt able to walk or do basic things like buttoning a shirt or lifting a pen off a countertop.

If youre undergoing chemotherapy and start to experience symptomsnumbness, tingling, pain or weakness in the hands and feetmake sure to let your oncologist know so that you can take steps to relieve the symptoms and prevent permanent nerve damage.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Manojkumar Bupathi is a medical oncologist with Rocky Mountain Cancer Centers. Read More

Originally posted here:
How Do You Deal With The Painful Tingling of Neuropathy? A Side Effect of Chemotherapy for Ovarian Cancer - SurvivorNet

This report studies the Chemotherapy Induced Peripheral Neuropathy Treatment Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Chemotherapy Induced Peripheral Neuropathy Treatment Market analysis segmented by companies, region, type and applications in the report.

Market Segment by Companies: Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma, and more

Request a Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=coleofduty&utm_medium=39

Chemotherapy Induced Peripheral Neuropathy Treatment Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Chemotherapy Induced Peripheral Neuropathy Treatment Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers:

Research Objectives:

Browse More Details @ https://www.reportsandmarkets.com/reports/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-professional-survey-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024?utm_source=coleofduty&utm_medium=39

The Chemotherapy Induced Peripheral Neuropathy Treatment Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents:

Key questions answered in this report:

Get Complete Report @ https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=3323528&utm_source=coleofduty&utm_medium=39

About Us:

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serves our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Continue reading here:
Chemotherapy Induced Peripheral Neuropathy Treatment Industry Growth Analysis 2020-2026 with Market Share, Size, Trends, Revenue, CAGR and SWOT...

The report on the Chemotherapy Induced Peripheral Neuropathy Treatment market provides a birds eye view of the current proceeding within the Chemotherapy Induced Peripheral Neuropathy Treatment market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Chemotherapy Induced Peripheral Neuropathy Treatment market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Chemotherapy Induced Peripheral Neuropathy Treatment market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Chemotherapy Induced Peripheral Neuropathy Treatment market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Chemotherapy Induced Peripheral Neuropathy Treatment market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2638040&source=atm

The major players profiled in this Chemotherapy Induced Peripheral Neuropathy Treatment market report include:

Segment by Type, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented intoCalcium Channel 2-delta LigandsAntidepressantsOpioidsOthers

Segment by Application, the Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented intoPlatinum AgentsTaxanesVinca AlkaloidsOthers

Regional and Country-level AnalysisThe Chemotherapy Induced Peripheral Neuropathy Treatment market is analysed and market size information is provided by regions (countries).The key regions covered in the Chemotherapy Induced Peripheral Neuropathy Treatment market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Chemotherapy Induced Peripheral Neuropathy Treatment Market Share AnalysisChemotherapy Induced Peripheral Neuropathy Treatment market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Chemotherapy Induced Peripheral Neuropathy Treatment business, the date to enter into the Chemotherapy Induced Peripheral Neuropathy Treatment market, Chemotherapy Induced Peripheral Neuropathy Treatment product introduction, recent developments, etc.The major vendors covered:Aptinyx IncAsahi Kasei Pharma CorpRegenacy PharmaceuticalsMAKScientific LLCMetys Pharmaceuticals AGNemus Bioscience IncPledPharmaSova Pharmaceuticals IncDermaXon LLCKineta IncKrenitsky Pharmaceuticals IncPeriphaGenApexian PharmaWinSanTorSolasia Pharma K.K.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2638040&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2638040&source=atm

Read the original:
COVID-19 impact: Chemotherapy Induced Peripheral Neuropathy Treatment Market : In-depth Study on Industry Size and Analysis on Emerging Growth Factors...